ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

linsitinib

Also written as “OSI-906” and “Linsitinib”.

Its studies are mostly in Graves Ophthalmopathy · Carcinoma, Non-Small-Cell Lung · Ovarian Neoplasms · Adrenocortical Carcinoma · Carcinoma, Hepatocellular, led by 2 companies.

Drug pageLinsitinib: every studyAll 27 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 17, 200913 company-led studies, 2 open or runningNext primary completion: Jun 30, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Astellas Pharmaits history only100 open or runningphase 3since Jun 17, 2009Aug 7, 2007none ahead
Sling Therapeutics32 open or runningphase 3since Mar 2, 2022Mar 2, 2022Jun 30, 2028phase 3 · NCT07753603

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sling Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 2, 2022First study: phase 3 study in Graves OphthalmopathyFirst studyNCT05276063 · 90 enrolled · United States, Canada, Italy and more
  2. Oct 16, 2023Phase 3 study in Graves OphthalmopathyNCT06112340 · 75 planned · United States
  3. Aug 3, 2026Phase 3 study in Graves OphthalmopathyNCT07753603 · 130 planned · United States

Ahead

  1. Jun 30, 2028Primary completion: phase 3 study in Graves OphthalmopathyNCT07753603

TargetBeta

IGF1R →INSR →read by rule
“An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) ”NCIt, by rule
“Insulin-like growth factor I receptor inhibitor; Insulin receptor inhibitor”ChEMBL 37, by rule

Studies

All 3 Sling Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07753603Graves Ophthalmopathy · United States3RecruitingJun 30, 2028130
NCT06112340Graves Ophthalmopathy · United States3RecruitingJun 202675
NCT05276063Graves Ophthalmopathy · United States, Canada, Italy and more3CompletedOct 15, 202490

How it is read

Names in the registry

  • “OSI-906”, 9 entries
  • “linsitinib”, 3 entries
  • “Linsitinib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.